Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer
NCT00652054
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
39
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG:
S-1
Sponsor
Taiho Oncology, Inc.
Collaborators
[object Object]